Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Porst

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
The Journal of Sexual Medicine|August 30, 2014
EFS/ESSM-Certified Psychosexologist with mark of excellenceLior Lowenstein, Francesca Tripodi, Yacov Reisman, et al.
The Journal of Sexual Medicine|June 30, 2010
Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunctionHartmut Porst, Sidney Glina, David Ralph, et al.
The Journal of Sexual Medicine|March 21, 2007
Development and validation of the quality of erection questionnaireHartmut Porst, Claire Gilbert, Suzanne Collins, et al.
Urology|July 24, 2013
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesHartmut Porst, Matthias Oelke, Evan R Goldfischer, et al.
BMC Urology|November 14, 2015
Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbiditiesDimitrios Hatzichristou, Gianluca d'Anzeo, Hartmut Porst, et al.
Urology|July 3, 2003
ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunctionAndreas Eisenhardt, Herbert Sperling, Ekkehard Hauck, et al.
European Urology|May 5, 2009
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasiaHartmut Porst, Kevin T McVary, Francesco Montorsi, et al.
European Urology|December 21, 2016
Corrigendum to "Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia" [Eur Urol 2009;56:727-36]Hartmut Porst, Kevin T McVary, Francesco Montorsi, et al.
The Journal of Sexual Medicine|June 29, 2011
A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitorsFrancesco Montorsi, Antonio Aversa, Ignacio Moncada, et al.
BJU International|October 27, 2018
Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre studyIgnacio Moncada, Pramod Krishnappa, Javier Romero, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
The Journal of Sexual Medicine|August 30, 2014
EFS/ESSM-Certified Psychosexologist with mark of excellenceLior Lowenstein, Francesca Tripodi, Yacov Reisman, et al.
The Journal of Sexual Medicine|June 30, 2010
Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunctionHartmut Porst, Sidney Glina, David Ralph, et al.
The Journal of Sexual Medicine|March 21, 2007
Development and validation of the quality of erection questionnaireHartmut Porst, Claire Gilbert, Suzanne Collins, et al.
Urology|July 24, 2013
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studiesHartmut Porst, Matthias Oelke, Evan R Goldfischer, et al.
BMC Urology|November 14, 2015
Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbiditiesDimitrios Hatzichristou, Gianluca d'Anzeo, Hartmut Porst, et al.
Urology|July 3, 2003
ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunctionAndreas Eisenhardt, Herbert Sperling, Ekkehard Hauck, et al.
European Urology|May 5, 2009
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasiaHartmut Porst, Kevin T McVary, Francesco Montorsi, et al.
European Urology|December 21, 2016
Corrigendum to "Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia" [Eur Urol 2009;56:727-36]Hartmut Porst, Kevin T McVary, Francesco Montorsi, et al.
The Journal of Sexual Medicine|June 29, 2011
A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitorsFrancesco Montorsi, Antonio Aversa, Ignacio Moncada, et al.
BJU International|October 27, 2018
Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre studyIgnacio Moncada, Pramod Krishnappa, Javier Romero, et al.
Pageof 7